Semaglutide altered 467 genes in brown adipose tissue while tirzepatide changed only 40, but tirzepatide modulated unique anti-inflammatory and metabolic targets that may explain its enhanced clinical effects beyond GLP-1 signaling alone.
467 vs 40 genes altered in brown fatSemaglutide changed expression of 467 genes in brown adipose tissue while tirzepatide altered only 40, but tirzepatide's unique targets include key anti-inflammatory genes like Il1b
What the researchers found
Both semaglutide and tirzepatide reduced body weight, improved lipid profiles, and enhanced insulin sensitivity in obese mice. However, their transcriptomic effects on brown adipose tissue were dramatically different: semaglutide modulated 467 differentially expressed genes (199 down, 268 up) compared to only 40 for tirzepatide (20 down, 20 up).
Three shared targets were identified (Cyp1a1, Hsd11b1, Atp1a3) that enhance insulin sensitivity and metabolism. Tirzepatide uniquely modulated three additional targets — Tfrc (transferrin receptor, involved in iron metabolism), Ptger4 (prostaglandin receptor, anti-inflammatory), and Il1b (interleukin-1β, a key inflammatory mediator) — potentially explaining tirzepatide's enhanced anti-inflammatory and metabolic regulatory effects compared to GLP-1-only agonists.
Why it matters
The clinical observation that tirzepatide produces greater weight loss than semaglutide in head-to-head trials has raised questions about what the additional GIP receptor activation contributes beyond GLP-1 effects alone. This study provides molecular-level answers: tirzepatide modulates distinct anti-inflammatory genes in brown fat that semaglutide does not, suggesting the dual-receptor approach offers qualitatively different — not just quantitatively stronger — metabolic effects. These molecular targets could inform the development of next-generation obesity drugs.
How the study worked
Twenty-eight male C57BL/6J mice were divided into four groups: standard diet control (n=7) and three high-fat, high-fructose diet groups receiving saline, semaglutide, or tirzepatide (n=7 each) via subcutaneous injection for 7 weeks. Researchers assessed metabolic parameters (body weight, glucose, lipids, insulin), BAT morphology, and performed RNA sequencing on BAT with bioinformatic analysis (GO, KEGG, PPI). Key findings were validated by RT-qPCR.
What this study cannot tell us
This is a mouse study, and brown fat biology differs between mice and humans — humans have much less BAT relative to body weight. The study used a 7-week treatment period, which may not capture long-term transcriptomic adaptations. With n=7 per group, statistical power for detecting small gene expression changes is limited. The functional significance of the identified gene targets was inferred from bioinformatics rather than directly validated experimentally (e.g., through gene knockout studies). Drug doses may not be directly comparable between semaglutide and tirzepatide in mouse models.
How to read the evidence
This is a preclinical mouse study with RNA sequencing and bioinformatic analysis. The experimental design is solid (randomized, controlled, validated by RT-qPCR), but the findings are limited to mouse brown fat and require human validation.
When this study was published
Published in 2025, this is a very recent study addressing one of the most active questions in metabolic pharmacology — what molecular differences underlie the clinical differences between semaglutide and tirzepatide.
The bigger picture
Brown adipose tissue has emerged as a key therapeutic target for obesity and metabolic disease because it burns calories to generate heat rather than storing energy. Understanding how different incretin drugs affect BAT gene expression helps explain their metabolic benefits beyond appetite suppression. The dramatic difference in gene expression scale (467 vs 40 genes) with qualitatively distinct targets challenges the assumption that tirzepatide simply 'does more of the same' as semaglutide — instead, the GIP receptor component appears to activate fundamentally different molecular programs in brown fat.
Questions still open
- Do the same transcriptomic differences between semaglutide and tirzepatide occur in human brown adipose tissue?
- Is tirzepatide's modulation of Il1b in BAT clinically significant — does it translate to measurably lower systemic inflammation in patients?
- Why does semaglutide alter over 10 times more genes than tirzepatide in BAT, and does this broader transcriptomic effect have functional consequences?
Common questions
What is brown fat and why does it matter for weight loss drugs?
Does this explain why tirzepatide seems to work better than semaglutide?
Read the original research
Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet.
Frontiers in nutrition, 12, 1659233
Citation
Ma, Tianyi; Song, Fanfan; Pan, Yongning; He, Ying; Cao, Xinming; Zhang, Yan; Song, Guangyao; Ren, Luping. (2025). Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet.. Frontiers in nutrition, 12, 1659233. https://doi.org/10.3389/fnut.2025.1659233